These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38709907)

  • 1. EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance.
    Kim Y; Jee S; Kim H; Paik SS; Choi D; Yoo SH; Shin SJ
    Oncologist; 2024 Aug; 29(8):e1051-e1060. PubMed ID: 38709907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
    Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
    Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human epidermal growth factor receptor 2, epidermal growth factor receptor, and c-MET overexpression and survival in biliary tract cancer: A meta-analysis.
    Zhou W; Jiang C; Zhan N; Lv X; Fan L; Ninu M
    J Cancer Res Ther; 2018; 14(Supplement):S28-S35. PubMed ID: 29578146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
    Pignochino Y; Sarotto I; Peraldo-Neia C; Penachioni JY; Cavalloni G; Migliardi G; Casorzo L; Chiorino G; Risio M; Bardelli A; Aglietta M; Leone F
    BMC Cancer; 2010 Nov; 10():631. PubMed ID: 21087480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
    Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR and HER2 expression in advanced biliary tract cancer.
    Harder J; Waiz O; Otto F; Geissler M; Olschewski M; Weinhold B; Blum HE; Schmitt-Graeff A; Opitz OG
    World J Gastroenterol; 2009 Sep; 15(36):4511-7. PubMed ID: 19777609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
    Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
    Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.
    Kawamoto T; Ishige K; Thomas M; Yamashita-Kashima Y; Shu S; Ishikura N; Ariizumi S; Yamamoto M; Kurosaki K; Shoda J
    J Gastroenterol; 2015 Apr; 50(4):467-79. PubMed ID: 25112701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.
    Nakazawa K; Dobashi Y; Suzuki S; Fujii H; Takeda Y; Ooi A
    J Pathol; 2005 Jul; 206(3):356-65. PubMed ID: 15892172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer.
    Hiraoka N; Nitta H; Ohba A; Yoshida H; Morizane C; Okusaka T; Nara S; Esaki M; Kishi Y; Shimada K
    Hum Pathol; 2020 Nov; 105():9-19. PubMed ID: 32891647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.
    Peraldo-Neia C; Cavalloni G; Fenocchio E; Cagnazzo C; Gammaitoni L; Cereda S; Nasti G; Satolli MA; Aprile G; Reni M; Avallone A; Spadi R; Venesio T; Martin V; Doglioni C; Frattini M; Aglietta M; Leone F
    PLoS One; 2018; 13(1):e0191593. PubMed ID: 29352306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification.
    Tanizaki J; Okamoto I; Sakai K; Nakagawa K
    Br J Cancer; 2011 Sep; 105(6):807-13. PubMed ID: 21847121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.
    Kwak Y; Yun S; Nam SK; Seo AN; Lee KS; Shin E; Oh HK; Kim DW; Kang SB; Kim WH; Lee HS
    J Transl Med; 2017 Aug; 15(1):167. PubMed ID: 28764718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of the co-expression of EGFR and HER2 in adenocarcinoma of the uterine cervix.
    Ueda A; Takasawa A; Akimoto T; Takasawa K; Aoyama T; Ino Y; Nojima M; Ono Y; Murata M; Osanai M; Hasegawa T; Saito T; Sawada N
    PLoS One; 2017; 12(8):e0184123. PubMed ID: 28859123
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Sanchez-Vega F; Hechtman JF; Castel P; Ku GY; Tuvy Y; Won H; Fong CJ; Bouvier N; Nanjangud GJ; Soong J; Vakiani E; Schattner M; Kelsen DP; Lefkowitz RA; Brown K; Lacouture ME; Capanu M; Mattar M; Qeriqi B; Cecchi F; Tian Y; Hembrough T; Nagy RJ; Lanman RB; Larson SM; Pandit-Taskar N; Schöder H; Iacobuzio-Donahue CA; Ilson DH; Weber WA; Berger MF; de Stanchina E; Taylor BS; Lewis JS; Solit DB; Carrasquillo JA; Scaltriti M; Schultz N; Janjigian YY
    Cancer Discov; 2019 Feb; 9(2):199-209. PubMed ID: 30463996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.
    Augustin J; Gabignon C; Scriva A; Menu L; Calmel C; Scatton O; Paye F; Fléjou JF; Praz F; Cervera P; Wendum D
    Virchows Arch; 2020 Jul; 477(1):33-45. PubMed ID: 32447492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm.
    Park CK; Park JS; Kim HS; Rha SY; Hyung WJ; Cheong JH; Noh SH; Lee SK; Lee YC; Huh YM; Kim H
    Oncotarget; 2016 Nov; 7(44):72099-72112. PubMed ID: 27765925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
    Galdy S; Lamarca A; McNamara MG; Hubner RA; Cella CA; Fazio N; Valle JW
    Cancer Metastasis Rev; 2017 Mar; 36(1):141-157. PubMed ID: 27981460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.